eli lilly glp 1 market share Explore the Global GLP-1 Receptor Agonist — Analysis of Key Trends, Regional Growth, Top Players, and a 10-Year Forecast from 2026 to 2036 Eli Lilly & Novo Nordisk

In my experience, consistency matters

[Accessed on 11 June 2026] Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (2025)

The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model

Compared to patients treated with sodium-dependent glucose transporters 2 (SGLT2) inhibitors as monotherapy, those receiving GLP-1RAs for type 2 diabetes exhibited a significantly increased risk of thyroid hyperplasia and thyroid cancer [22]

I had been curious about a GLP-1 for at least a year now and finally decided to try it

The EMA and FDA imposed a respective label (52, 53)